Benefits of Bone-Modifying Agents Confirmed in Breast Cancer

Bone-modifying agents incorporated into adjuvant therapy for breast cancer improve bone mineral density and reduce the risk of fractures. The effect on clinical outcomes, however, is less certain, although data suggest small reductions in bone metastases and breast cancer mortality in women undergoing ovarian function suppression who receive adjuvant bisphosphonates.

 MedPage Today

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.